Identification of blood lipid markers of docetaxel treatment in prostate cancer patients

Abstract Docetaxel is commonly used for treatment of castration-resistant prostate cancer. Unfortunately, many prostate cancer patients develop resistance to docetaxel. Clinical markers less invasive than biopsies, such as blood samples, would be ideal for monitoring and predicting patient treatment...

Full description

Bibliographic Details

Published in:	Scientific Reports
Main Authors:	Morgan C. Finnerty, Franklin E. Leach, Yousef Zakharia, Kenneth G. Nepple, Michael G. Bartlett, Michael D. Henry, Brian S. Cummings
Format:	Article
Language:	English
Published:	Nature Portfolio 2024-09-01
Subjects:	Docetaxel Prostate cancer Lipidomics Drug resistance Biomarker Clinical
Online Access:	https://doi.org/10.1038/s41598-024-73074-8